What is Enclomiphene?
Enclomiphene is the trans-isomer of Clomiphene Citrate (Clomid) — isolated to deliver the receptor antagonism effects without the unwanted estrogenic agonism associated with the cis-isomer (zuclomiphene). It is a selective estrogen receptor modulator (SERM) primarily researched for its ability to stimulate the hypothalamic-pituitary-testicular (HPT) axis.
Research interest in Enclomiphene has grown significantly due to its potential to restore endogenous testosterone production after androgen suppression, while avoiding oestrogen-related side effects often seen with traditional Clomid protocols. For research purposes only.
⚠ Research Purposes Only: Enclomiphene is a research chemical. While it has undergone clinical trials for hypogonadism (secondary), it is not approved by the FDA or MHRA as a standalone treatment for human use in most jurisdictions.
Enclomiphene vs Clomiphene — Research Comparison
| Parameter | Enclomiphene | Clomiphene (Clomid) |
|---|---|---|
| Isomer Type | Trans (E-isomer) | Mixture (E + Z isomers) |
| Estrogenic Agonism | Low / minimal | Moderate (Z-isomer) |
| HPT Axis Stimulation | Strong | Moderate |
| Half-Life | ~10 hours | 5–7 days (zuclomiphene) |
| Visual Side Effects | Reduced vs Clomid | Possible (Z-isomer) |
| Research Context | Secondary hypogonadism, PCT | Ovulation induction, PCT |
Mechanism of Action
Enclomiphene works by blocking estrogen receptors in the hypothalamus and pituitary. This prevents estrogen's normal negative feedback on gonadotropin-releasing hormone (GnRH), causing the pituitary to secrete more LH (luteinising hormone) and FSH (follicle-stimulating hormone). Elevated LH then signals the testes to produce testosterone.
Because enclomiphene clears the system faster than the zuclomiphene isomer (which accumulates over weeks), research protocols using pure enclomiphene show faster washout and potentially fewer persistent side effects.
PCT Research Context
In post-cycle research contexts — particularly following SARM or androgen protocols — researchers frequently study enclomiphene alongside compounds like TUDCA for liver support. Its clean mechanism and faster half-life make it one of the most studied SERM compounds for HPTA recovery research.
Clinical trials by Repros Therapeutics (ZA-003 trial) showed enclomiphene 12.5–25mg significantly raised testosterone and LH/FSH levels in men with secondary hypogonadism, with a more favourable profile than testosterone replacement in maintaining spermatogenesis.
🔬 Where to Source Enclomiphene for Research (USA & UK)
For USA and UK researchers, RCD.bio stocks Enclomiphene with third-party certificates of analysis. All products are for research purposes only and not approved for human consumption.
Visit RCD.bio →⚠ Affiliate link — use code Tomjunkie for 20% off. Research purposes only.
Frequently Asked Questions
Enclomiphene is the trans-isomer (E-isomer) of clomiphene, isolated to remove the estrogenic agonism of the cis-isomer (zuclomiphene). This gives it a cleaner HPT axis stimulation profile with fewer estrogen-related side effects. For research purposes only.
In clinical trials for secondary hypogonadism, enclomiphene significantly raised LH, FSH and serum testosterone levels by blocking estrogenic negative feedback on the hypothalamus and pituitary. For research purposes only.
Enclomiphene (Androxal by Repros Therapeutics) completed Phase III trials for secondary hypogonadism but did not receive FDA approval. It is sold as a research chemical by licensed vendors.
RCD.bio (Research Chemical Depot) stocks Enclomiphene with certificates of analysis. All products are for research purposes only and not approved for human consumption.